会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 13. 发明申请
    • Method for Reducing Mercaptans in Hydrocarbons
    • 减少碳氢化合物中硫醇的方法
    • US20120103871A1
    • 2012-05-03
    • US12914275
    • 2010-10-28
    • Zunqing HeZhen ZhouLin Li
    • Zunqing HeZhen ZhouLin Li
    • C10G27/02C10G19/00C10G27/00
    • C10G27/02C10G27/06C10G33/00C10G2300/1033C10G2300/202C10G2400/08
    • A method for reducing mercaptan concentration in a liquid hydrocarbon, comprising: contacting a mercaptan-rich liquid hydrocarbon having a first concentration of mercaptan sulfur with a composition comprising an oxidizing agent and water wherein the molar ratio of the oxidizing agent to mercaptan sulfur in the mercaptan-rich liquid hydrocarbon is from 3:1 to 10:1; and separating the water from the liquid hydrocarbon to yield a mercaptan-depleted liquid hydrocarbon having a second concentration of mercaptan sulfur, the second concentration being less than the first concentration; wherein a major amount of mercaptan compounds in the mercaptan-rich liquid hydrocarbon are converted to at least one sulfur oxoacid or salt thereof, having the formula: [RSOx]nY wherein R is a hydrocarbyl group; x is an integer from 1 to 3; n is 1 or 2; and Y is hydrogen, an alkaline metal, or alkaline earth metal.
    • 一种用于降低液体烃中硫醇浓度的方法,包括:使具有第一浓度的硫醇硫的富硫醇液体烃与包含氧化剂和水的组合物接触,其中硫醇中的氧化剂与硫醇的摩尔比 富液体烃为3:1至10:1; 并从液态烃中分离出水,得到具有第二浓度的硫醇硫的硫醇贫化液态烃,第二浓度小于第一浓度; 其中所述富硫醇溶液中的主要量的硫醇化合物被转化成至少一种具有下式的硫代酸或其盐:其中R是烃基的[RSO x] n Y; x是1至3的整数; n为1或2; Y是氢,碱金属或碱土金属。
    • 19. 发明申请
    • Beta-L-nucleosides and use thereof as pharmaceutical agents for the treatment of viral diseases
    • β-L-核苷及其用作治疗病毒性疾病的药剂
    • US20060217345A1
    • 2006-09-28
    • US11373062
    • 2006-03-10
    • Eckart MatthesMartin Janta-LipinskiHans WillHuseyin SirmaLin Li
    • Eckart MatthesMartin Janta-LipinskiHans WillHuseyin SirmaLin Li
    • A61K31/7072A61K31/675A61K31/513C07H19/04C07H19/12C07F9/6512
    • C07H19/06C07H19/09
    • Nucleoside analogs, nucleic acids and pharmaceutical agents comprising same, and to the use of said nucleoside analogs, nucleic acids and pharmaceutical agents in the diagnosis, prophylaxis or therapy of a viral, bacterial, fungicidal and/or parasitic infection, or of cancer, particularly of hepatitis infections. The invention also relates to a method for the preparation of said nucleoside analogs and to a kit and the use thereof in the prophylaxis and therapy of viral diseases, particularly of hepatitis infections. As stated in 37 C.F.R. §1.72(b): A brief abstract of the technical disclosure in the specification must commence on a separate sheet, preferably following the claims, under the heading “Abstract of the Disclosure.” The purpose of the abstract is to enable the Patent and Trademark Office and the public generally to determine quickly from a cursory inspection the nature and gist of the technical disclosure. The abstract shall not be used for interpreting the scope of the claims. Therefore, any statements made relating to the abstract are not intended to limit the claims in any manner and should not be interpreted as limiting the claims in any manner.
    • 核苷类似物,核酸和包含其的药物,以及所述核苷类似物,核酸和药物在诊断,预防或治疗病毒,细菌,杀真菌和/或寄生虫感染或癌症中的用途,特别是 的肝炎感染。 本发明还涉及制备所述核苷类似物和试剂盒的方法及其用于预防和治疗病毒性疾病,特别是肝炎感染的用途。 如37 C.F.R. §1.72(b):说明书中技术性披露的简要摘要必须在单独的表格上开始,优选按照权利要求,在“披露摘要”标题下。 摘要的目的是使专利商标局和公众一般能够从粗略检查中快速确定技术披露的性质和要点。 摘要不得用于解释权利要求的范围。 因此,与摘要有关的任何陈述不旨在以任何方式限制权利要求,也不应被解释为以任何方式限制权利要求。